Journal of Oncology / 2009 / Article / Tab 8

Review Article

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Table 8

Management of anti-EGFR-associated rash and common terminology criteria for adverse events v3.0 (CTCAE), National Cancer Institute.

CTC GradeRashManagement

1Macular or papular eruption or erythema AsymptomaticTopical antibiotic agents (metronidazole, erythromycin, and clindamycin lotion) Corticosteroid cream if an extensive inflammatory component exists

2Macular or papular eruption or erythema Symptomatic covering <50% of bodyAnti-inflammatory oral antibiotics (minocycline or doxycycline) Corticosteroid cream if an extensive inflammatory component exists

3Macular or papular eruption or erythema Symptomatic covering >50% of bodyAnti-inflammatory oral antibiotics (minocycline or doxycycline) Oral corticosteroids EGFR therapy should be held until the acute inflammatory phase has resolved

4Generalized exfoliative, ulcerative, or bullouis dermatitisAnti-inflammatory oral antibiotics (minocycline or doxycycline) Oral corticosteroids (Medrol-dose pack) EGFR therapy should be held until the acute inflammatory phase has resolved

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.